paclitaxel

P1/2, N=54, Active, not recruiting, CanariaBio Inc. | Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Apr 2024 --> Oct 2025

P3, N=49, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

Silibinin potentiates paclitaxel cytotoxicity by suppressing H19 transcription, offering a potential strategy to overcome paclitaxel resistance. The combination promotes apoptosis via caspase activation, highlighting a novel synergistic therapeutic approach in breast cancer treatment.

Silymarin also reduced Caspase-3 levels while increasing Bcl-2 protein expression, an antiapoptotic protein. These results suggest that silymarin has significant therapeutic potential for reducing Paclitaxel-induced cardiotoxicity via its antioxidant, anti-inflammatory, and anti-apoptotic properties.

P2/3, N=30, Not yet recruiting, Rakuten Medical Inc.

In the paclitaxel and oxaliplatin CIPN mouse model, administration of HS-276 significantly reduced mechanical allodynia comparable to gabapentin. PERSPECTIVE: This manuscript demonstrates the therapeutic potential of TAK1-targeted therapies for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). This new treatment has the potential to protect CIPN patients from development of debilitating and dose-limiting CIPN-associated pain, and allow patients to remain on life-saving chemotherapeutic treatments for longer.

We show that CG enhances the chemical sensitivity of TNBC by regulating the γ-secretase/RBPJ-PXR axis.

P2, N=40, Completed, Asan Medical Center | Recruiting --> Completed

P2, N=162, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting

The study identifies PDCD4 as a key therapeutic target and demonstrates that the PTX-TP@PLGA-iRGD nanocomplex enhances drug potency, selectivity and molecular engagement. This study offers a promising strategy to overcome metastasis and chemoresistance in colon cancer.

Moreover, PCA improved sperm density and motility, decreased abnormal morphology, and partially restored reduced testosterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels. Overall, the findings indicate that PCA may serve as a potential therapeutic agent against PTX-induced testicular damage through its strong antioxidant and cytoprotective effects.

He subsequently received ramucirumab-based therapy, paclitaxel, and irinotecan...Pembrolizumab combined with capecitabine and oxaliplatin (CAPOX) was initiated as fifth-line therapy, resulting in notable regression of hepatic and nodal metastases. This case underscores the clinical importance of early MSI/MMR and genomic testing and suggests that re-administration of ICI plus chemotherapy may be a therapeutic option for selected patients with advanced gastric cancer who initially show limited response to ICI-based therapy.